Between 2013 and 2018, Asiya has worked at bluebird bio in Cambridge MA in Business Development, Alliance Management and Research Strategy roles. (forbion.com)
In the biotechnology sector, Canter Fitzgerald analyst Elemer Piros increased his price target for bluebird bio Inc (NASDAQ: BLUE) from $ 39 to $ 58, but he maintains an Underweight rating. (benzinga.com)
Sean currently conducts cancer research at Bluebird Bio in Cambridge. (ragoninstitute.org)